Skip to content

Trial Summary

A Study of Zanubrutinib (BGB-3111) Versus Ibrutinib in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma.

Acronym:

ALPINE

ACTRN/NCT /ethics:

NCT03734016

Scientific title:

A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphocytic Lymphoma

Sponsor / Cooperative group:

BeiGene

Trial & Patient Characteristics

Cancer TypeLymphoma
Trial TypeTreatment
PhasePhase III
Age Range18 years and older
SexBoth
Tumour Stream Lymphoma
Cancer StageLocally Recurrent or Locally Advanced
Anticipated Start Date-
Anticipated End Date-

Participating Hospitals

HospitalAshford Cancer Centre Research
Clinical Trial CoordinatorSue Yeend
Emailsyeend@adelaidecancercentre.com.au
Phone08 8292 2240
Principal InvestigatorDr Stanley Cheung
Recruitment StatusRecruiting